Rani Therapeutics Holdings, Inc. (RANI) stock
RANINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3043% above fair value
$0.65+0.09 (+15.86%)
Close on Nov 18, 2026Market cap $90.34MP/E –Yield –
Rani Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Rani Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $4.88M, up 306.4% year over year. For fiscal 2025 it was $1.63M, up 58.9% from the year before. The highest annual figure on record is $2.72M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.63M | +58.9% |
| FY2024 | Dec 31, 2024 | $1.03M | – |
| FY2023 | Dec 31, 2023 | $0 | – |
| FY2022 | Dec 31, 2022 | $0 | -100.0% |
| FY2021 | Dec 31, 2021 | $2.72M | +488.1% |
| FY2020 | Dec 31, 2020 | $462.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.71M | – |
| Q1 FY2026 | Mar 31, 2026 | $1.71M | +893.0% |
| Q4 FY2025 | Dec 31, 2025 | $1.46M | +42.1% |
| Q3 FY2025 | Sep 30, 2025 | $0 | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | – |
| Q1 FY2025 | Mar 31, 2025 | $172.00K | – |
| Q4 FY2024 | Dec 31, 2024 | $1.03M | – |
| Q3 FY2024 | Sep 30, 2024 | $0 | – |
| Q2 FY2024 | Jun 30, 2024 | $0 | – |
| Q1 FY2024 | Mar 31, 2024 | $0 | – |
| Q4 FY2022 | Dec 31, 2022 | $0 | – |
| Q3 FY2022 | Sep 30, 2022 | $0 | -100.0% |
| Q2 FY2022 | Jun 30, 2022 | $0 | -100.0% |
| Q4 FY2021 | Dec 31, 2021 | $0 | -100.0% |
| Q3 FY2021 | Sep 30, 2021 | $0 | -100.0% |
| Q2 FY2021 | Jun 30, 2021 | $1.96M | +3168.3% |
| Q1 FY2021 | Mar 31, 2021 | $756.00K | – |
| Q4 FY2020 | Dec 31, 2020 | $210.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $108.00K | – |
| Q2 FY2020 | Jun 30, 2020 | $60.00K | – |
See a number that looks wrong?